Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon-alpha · 3 trials · 4 indications
Time to resolution of influenza symptoms defined as all flu symptoms scored as \<=1 and change in viral load (RT-PCR).
Number of subjects in each group meeting the definition of influenza-like illness during treatment (i.e. those subject reporting one or more moderate to severe cold/flu symptoms during the treatment period).
Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area
| Arm | Type | Description |
|---|---|---|
| Interferon-alpha | EXPERIMENTAL | Interferon-alpha 150 IU lozenges bid for 5 days |
| maltose | PLACEBO_COMPARATOR | maltose 200 mg maltose lozenges bid for 5 days |
| placebo | PLACEBO_COMPARATOR | placebo lozenges |
| IFN lozenges | EXPERIMENTAL | 500 IU Interferon-alpha lozenges for oral dissolution |
| placebo lozenges | PLACEBO_COMPARATOR | 200 mg lozenges containing anhydrous crystalline maltose |
| Name | Type | Description |
|---|---|---|
| Interferon-alpha | DRUG | 150 IU lozenges bid for 5 days |
| Oseltamivir | DRUG | 75 mg capsules bid for 5 days |
| maltose | OTHER | 200 mg maltose lozenges bid for 5 days |
| placebo | OTHER | placebo lozenges for oral dissolution taken once daily for 16 weeks |
Inclusion Criteria: * fever \>=38C * one or more respiratory symptoms (e.g. cough, rhinorrhea or sore throat) plus one or more constitutional symptoms (e.g. chills, headache, malaise and myalgias)of \< 48 hours' duration * body weight \> 40 kg * positive for influenza A (nasal swab rapid test) Exc...
Interferon-alpha is an investigational small molecule being studied for upper respiratory tract infections, papillomatosis, and influenza A virus infection. It is delivered as lozenges in clinical trials. The drug is not approved and remains in clinical development.
Interferon-alpha is being developed by Ainos, Inc. (NASDAQ: AIMD). The company is conducting clinical trials of the drug for infectious disease indications.
Interferon-alpha is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All three completed trials were Phase 2 studies.
Interferon-alpha has been studied in three completed Phase 2 trials: NCT00454181 for oral warts in HIV patients, NCT00895947 for prevention of winter colds and flu, and NCT01146535 for influenza treatment with oseltamivir.
Interferon-alpha is a small molecule that works by mimicking the body's natural interferon-alpha protein, which helps regulate immune responses against viral infections. It is being studied as lozenges for respiratory and viral conditions.
Interferon-alpha is a specific type of interferon, distinct from interferon-beta and interferon-gamma. It is being developed by Ainos, Inc. as a lozenge formulation for infectious disease indications.